Julie R. Larsen
Horsholm, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Long-term health care resource and cost savings with allergy immunotherapy: REACT study results.
Journal: The journal of allergy and clinical immunology. Global
Published: January 20, 2023
High baseline prevalence of atopic comorbidities and medication use in children treated with allergy immunotherapy in the REAl-world effeCtiveness in allergy immunoTherapy (REACT) study.
Journal: Frontiers in pediatrics
Published: January 03, 2023
Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study.
Journal: The Journal of allergy and clinical immunology
Published: September 21, 2022
Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma - Authors´ reply.
Journal: The Lancet regional health. Europe
Published: May 02, 2022
Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.
Journal: The Lancet regional health. Europe
Published: December 13, 2021
Real-world evidence: Methods for assessing long-term health and effectiveness of allergy immunotherapy.
Journal: The Journal of allergy and clinical immunology
Published: October 14, 2021
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.
Journal: CNS spectrums
Published: December 14, 2020
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.
Journal: Psychiatry research
Published: August 18, 2020
High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.
Journal: CNS spectrums
Published: January 01, 2019
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Journal: Acta psychiatrica Scandinavica
Published: October 25, 2018
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Journal: Diabetes, obesity & metabolism
Published: July 27, 2018
Last Updated: 09/26/2026